Acquiring Company
Redx Pharma
Acquired Company
Mersana Therapeutics
United Kingdom
CambridgeBiotechnologyHealth CareTherapeuticsBiotechnologyHealth CareTherapeuticsDescription
Redx Pharma has successfully acquired Mersana Therapeutics, expanding its oncology portfolio. This acquisition follows a reverse merger with Jounce Therapeutics. The merger aims to leverage combined technologies in developing cancer therapies. Investors are focusing on the future potential of the reshaped entity.
Who to call at Redx Pharma, and when
When Redx Pharma changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Redx Pharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Redx Pharma, from your own LinkedIn network
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Redx Pharma makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Mersana Therapeutics?
Mersana Therapeutics was acquired by Redx Pharma, based in United Kingdom. The deal was reported on June 19, 2026. Redx Pharma is a biotechnology company focused on developing treatments for cancer and fibrotic diseases. The company specializes in small molecule therapeutics. Redx Pharma is privately held and operates in Biotechnology.
When did Redx Pharma acquire Mersana Therapeutics?
Redx Pharma's acquisition of Mersana Therapeutics was reported on June 19, 2026. Redx Pharma has successfully acquired Mersana Therapeutics, expanding its oncology portfolio. This acquisition follows a reverse merger with Jounce Therapeutics. The merger aims to leverage combined technologies in developing cancer therapies. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Mersana Therapeutics do?
Mersana Therapeutics, Inc. is a biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. Their innovative ADC platform enables the design of more effective cancer therapies. It is privately held, operating in Biotechnology, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.